Madrigal Pharmaceuticals Inc
NASDAQ:MDGL

Watchlist Manager
Madrigal Pharmaceuticals Inc Logo
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Watchlist
Price: 347.45 USD 5.53% Market Closed
Market Cap: 7.6B USD
Have any thoughts about
Madrigal Pharmaceuticals Inc?
Write Note

Madrigal Pharmaceuticals Inc
Other Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Madrigal Pharmaceuticals Inc
Other Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Other Current Assets
$14m
CAGR 3-Years
55%
CAGR 5-Years
53%
CAGR 10-Years
17%
Abbvie Inc
NYSE:ABBV
Other Current Assets
$4.6B
CAGR 3-Years
2%
CAGR 5-Years
17%
CAGR 10-Years
-1%
Gilead Sciences Inc
NASDAQ:GILD
Other Current Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Other Current Assets
$3.1B
CAGR 3-Years
7%
CAGR 5-Years
-2%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Current Assets
$449.2m
CAGR 3-Years
-1%
CAGR 5-Years
21%
CAGR 10-Years
27%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Current Assets
$412m
CAGR 3-Years
-5%
CAGR 5-Years
13%
CAGR 10-Years
14%
No Stocks Found

Madrigal Pharmaceuticals Inc
Glance View

Market Cap
7.2B USD
Industry
Biotechnology

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company is headquartered in Conshohocken, Pennsylvania and currently employs 71 full-time employees. The company went IPO on 2007-02-06. The firm is focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The firm's product candidate, resmetirom, is a liver-directed, selective thyroid hormone receptor-Ăź (THR-Ăź) agonist developed as a once-daily oral pill to treat a number of disease states, including non-alcoholic steatohepatitis (NASH). NASH is a liver disease that affects people with metabolic diseases, such as obesity and diabetes and non-alcoholic fatty liver disease (NAFLD).

MDGL Intrinsic Value
250.51 USD
Overvaluation 28%
Intrinsic Value
Price

See Also

What is Madrigal Pharmaceuticals Inc's Other Current Assets?
Other Current Assets
14m USD

Based on the financial report for Sep 30, 2024, Madrigal Pharmaceuticals Inc's Other Current Assets amounts to 14m USD.

What is Madrigal Pharmaceuticals Inc's Other Current Assets growth rate?
Other Current Assets CAGR 10Y
17%

Over the last year, the Other Current Assets growth was 353%. The average annual Other Current Assets growth rates for Madrigal Pharmaceuticals Inc have been 55% over the past three years , 53% over the past five years , and 17% over the past ten years .

Back to Top